Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Mark M. Awad, Xinan Wang et al.|JAMA Oncology|2022Cited by 383
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V. Negrão, Sandip Pravin Patel, Haniel A. Araújo et al.|Cancer Discovery|2023Cited by 181
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung CancerBiagio Ricciuti, Mark M. Awad, Giuseppe Lamberti et al.|Journal of Clinical Oncology|2024Cited by 124
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancerBiagio Ricciuti, Jia Luo, Giuseppe Lamberti et al.|Annals of Oncology|2022Cited by 100
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLCJoao V. Alessi, Mark M. Awad, Arielle Elkrief et al.|Journal of Thoracic Oncology|2023Cited by 91